Published in Blood on December 20, 2007
Biomimetic delivery with micro- and nanoparticles. Adv Mater (2012) 1.25
Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. J Immunol Methods (2009) 1.10
Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. Clin Cancer Res (2008) 0.96
Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine (Lond) (2013) 0.88
Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion. Immunol Res (2010) 0.86
Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'. Immunotherapy (2010) 0.85
New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppression. Ann N Y Acad Sci (2010) 0.84
Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells. Immunology (2011) 0.82
Optimized staining and proliferation modeling methods for cell division monitoring using cell tracking dyes. J Vis Exp (2012) 0.81
Shaping the future of nanomedicine: anisotropy in polymeric nanoparticle design. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.80
Fas mediates cardiac allograft acceptance in mice with impaired T-cell-intrinsic NF-kappaB signaling. Transpl Int (2009) 0.79
Micro and nanoparticle drug delivery systems for preventing allotransplant rejection. Clin Immunol (2015) 0.78
Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells. J Interferon Cytokine Res (2012) 0.78
A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo. Oncotarget (2016) 0.76
Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells. J Vis Exp (2014) 0.75
An Antigen-Presenting and Apoptosis-Inducing Polymer Microparticle Prolongs Alloskin Graft Survival by Selectively and Markedly Depleting Alloreactive CD8(+) T Cells. Front Immunol (2017) 0.75
Tolerogenic Nanoparticles to Treat Islet Autoimmunity. Curr Diab Rep (2017) 0.75
Apoptosis by death factor. Cell (1997) 14.42
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 8.23
CD95's deadly mission in the immune system. Nature (2000) 5.55
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09
Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol (2002) 3.63
Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science (1996) 3.35
The evolution of adaptive immune systems. Cell (2006) 2.77
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70
Organ transplantation--how much of the promise has been realized? Nat Med (2005) 2.26
Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med (2003) 2.21
Cellular interactions in thymocyte development. Annu Rev Immunol (1996) 2.17
How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol (2005) 2.12
The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science (1998) 2.11
Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med (2005) 2.10
TNF receptor superfamily-induced cell death: redox-dependent execution. FASEB J (2006) 1.98
CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol (2000) 1.94
Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med (1995) 1.67
Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat Biotechnol (1998) 1.59
Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood (2006) 1.45
Recognition of a subregion of human proinsulin by class I-restricted T cells in type 1 diabetic patients. Proc Natl Acad Sci U S A (2005) 1.35
Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. Diabetes (2003) 1.30
Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol (2000) 1.27
Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity (2002) 1.19
Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med (1999) 1.10
CD95 ligand in graft rejection. Nature (1996) 1.09
Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol (2004) 1.09
Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood (2004) 1.06
Tumor counterattack: fact or fiction? Cancer Immunol Immunother (2005) 0.99
Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood (2006) 0.96
Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood (2004) 0.95
Antigen presenting cells expressing Fas ligand down-modulate chronic inflammatory disease in Fas ligand-deficient mice. J Clin Invest (2000) 0.93
In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol (2003) 0.93
Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J Immunol (2003) 0.91
Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells. Blood (2001) 0.89
Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol (1998) 0.89
The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. Methods (2003) 0.88
CD8+ T cell-mediated HLA-A*0201-restricted cytotoxicity to transaldolase peptide 168-176 in patients with multiple sclerosis. J Immunol (2005) 0.87
Killing of naive T cells by CD95L-transfected dendritic cells (DC): in vivo study using killer DC-DC hybrids and CD4(+) T cells from DO11.10 mice. Eur J Immunol (2002) 0.87
Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/CD95L)-expressing Killer-dendritic cells. Immunobiology (2004) 0.86
Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood (2002) 0.86
Antigen-specific induction of peripheral T cell tolerance in vivo by codelivery of DNA vectors encoding antigen and Fas ligand. Hum Gene Ther (2000) 0.85
HLA class I epitope discovery in type 1 diabetes. Ann N Y Acad Sci (2006) 0.84
Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity. Cell Death Differ (2006) 0.84
CTLA-4-Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells. Int Immunol (2001) 0.84
CTLA-4. FasL induces alloantigen-specific hyporesponsiveness. J Immunol (2003) 0.83
Treatment of chronic sialadenitis in a murine model of Sjögren's syndrome by local fasL gene transfer. Arthritis Rheum (2001) 0.83
Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells. Eur J Immunol (2001) 0.82
HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. Transplantation (1998) 0.82
Reduction of antiviral CD8 lymphocytes in vivo with dendritic cells expressing Fas ligand-increased survival of viral (lymphocytic choriomeningitis virus) central nervous system infection. J Immunol (2002) 0.81
Autoimmunity in the era of genomics and proteomics. Autoimmun Rev (2005) 0.81
Dendritic cells overexpressing Fas-ligand induce pulmonary vasculitis in mice. Clin Exp Immunol (2004) 0.81
Tolerance induction in clinical transplantation: the pending questions. Transplantation (2003) 0.80
Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy. J Immunol (2001) 0.77
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood (2007) 2.64
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother (2004) 2.42
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer (2006) 2.40
A novel arthritis in vivo fluorescence optical imaging technology pushed to the limits. Rheumatology (Oxford) (2012) 2.32
T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol (2002) 2.21
Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med (2003) 2.21
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother (2006) 2.20
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol (2012) 2.12
The value of colour Doppler sonography of the knee joint: a useful tool to discriminate inflammatory from non-inflammatory disease? Rheumatology (Oxford) (2013) 2.00
Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood (2014) 1.80
Ultrasound-guided sacroiliac joint injection in patients with established sacroiliitis: precise IA injection verified by MRI scanning does not predict clinical outcome. Rheumatology (Oxford) (2009) 1.80
Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) (2011) 1.68
Life hung by a thread: endurance of Antarctic fauna in glacial periods. Ecology (2008) 1.63
Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood (2005) 1.58
Antigen recognition induces phosphatidylserine exposure on the cell surface of human CD8+ T cells. Blood (2006) 1.45
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res (2006) 1.41
Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells. Blood (2004) 1.40
Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection. Rheumatology (Oxford) (2012) 1.39
Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol (2003) 1.36
Lectin microarrays identify cell-specific and functionally significant cell surface glycan markers. Glycobiology (2008) 1.28
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. Br J Haematol (2010) 1.25
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges (2013) 1.25
Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum (2002) 1.24
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression. Cancer Res (2012) 1.22
Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res (2009) 1.22
Development and evaluation of a novel ultrasound score for large joints in rheumatoid arthritis: one year of experience in daily clinical practice. Arthritis Care Res (Hoboken) (2012) 1.21
B220+ double-negative T cells suppress polyclonal T cell activation by a Fas-independent mechanism that involves inhibition of IL-2 production. J Immunol (2003) 1.20
TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol (2003) 1.20
The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells. FEBS Lett (2005) 1.19
18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin Rheumatol (2010) 1.12
Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. J Immunol Methods (2009) 1.10
Characterization of the immunoregulatory function of human TCR-αβ+ CD4- CD8- double-negative T cells. Eur J Immunol (2011) 1.09
Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev (2007) 1.09
Tumor metabolism as modulator of immune response and tumor progression. Semin Cancer Biol (2012) 1.09
Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res (2012) 1.08
Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol (2010) 1.08
Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer (2006) 1.07
Fas-mediated apoptosis regulates the composition of peripheral alphabeta T cell repertoire by constitutively purging out double negative T cells. PLoS One (2008) 1.05
Artificial antigen-presenting cells: artificial solutions for real diseases. Trends Mol Med (2005) 1.05
Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res (2007) 1.04
Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother (2011) 1.04
Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.03
Detection of antigen-specific T cells on p/MHC microarrays. J Mol Recognit (2007) 1.01
Heat shock protein 70 membrane expression and melanoma-associated marker phenotype in primary and metastatic melanoma. Melanoma Res (2003) 1.01
High-resolution alkenone palaeobarometry indicates relatively stable pCO(2) during the Pliocene (3.3-2.8 Ma). Philos Trans A Math Phys Eng Sci (2013) 1.01
Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. J Immunol Methods (2002) 1.00
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res (2009) 1.00
The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res (2003) 0.99
Dietary fatty acids modulate antigen presentation to hepatic NKT cells in nonalcoholic fatty liver disease. J Lipid Res (2010) 0.99
Dynamic regulation of functionally distinct virus-specific T cells. Proc Natl Acad Sci U S A (2010) 0.99
Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother (2010) 0.99
An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J Immunol Methods (2002) 0.99
In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother (2008) 0.99
Persisting right-sided chylothorax in a patient with chronic lymphocytic leukemia: a case report. J Med Case Rep (2011) 0.98
Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res (2006) 0.97
Gld mutation of Fas ligand increases the frequency and up-regulates cell survival genes in CD25+CD4+ TR cells. Int Immunol (2006) 0.97
Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically. Am J Pathol (2007) 0.96
Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. Clin Cancer Res (2008) 0.96
Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res (2008) 0.96
Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res (2008) 0.95
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. MAbs (2011) 0.95
Perioperative management of immunosuppression in rheumatic diseases--what to do? Rheumatol Int (2009) 0.95
Identification of beta-subunit of bacterial RNA-polymerase--a non-species-specific bacterial protein--as target of antibodies in primary biliary cirrhosis. Dig Dis Sci (2003) 0.95
Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges (2008) 0.94
Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumor. Int J Cancer (2011) 0.94
CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res (2007) 0.93
Fibrosing connective tissue disorders of the skin: molecular similarities and distinctions. J Dermatol Sci (2013) 0.93
Tumor-Induced Osteomalacia: an Up-to-Date Review. Curr Rheumatol Rep (2015) 0.92
Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. ACS Nano (2014) 0.92
Differential innate immune cell activation and proinflammatory response in Anaplasma phagocytophilum infection. Infect Immun (2007) 0.92
Fatal pulmonary failure attributable to viral pneumonia with human herpes virus 6 (HHV6) in a young immunocompetent woman. J Intensive Care Med (2005) 0.91
Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J Immunol (2003) 0.91
High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma. Cancer Res (2004) 0.91
Quantum dot fluorescence characterizes the nanoscale organization of T cell receptors for antigen. Biophys J (2011) 0.90
Sprouty-2 regulates HIV-specific T cell polyfunctionality. J Clin Invest (2014) 0.90
A new flow cytometric assay for the simultaneous analysis of antigen-specific elimination of T cells in heterogeneous T cell populations. J Immunol Methods (2009) 0.90
A patient with Pfeifer-Weber-Christian disease--successful therapy with cyclosporin A: case report. BMC Musculoskelet Disord (2010) 0.90
Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay. Immunobiology (2002) 0.90
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immunol (2006) 0.89
HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement. Clin Immunol (2004) 0.88
T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs. PLoS Negl Trop Dis (2013) 0.88
The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. Methods (2003) 0.88
Cryptococcosis mimicking cutaneous cellulitis in a patient suffering from rheumatoid arthritis: a case report. BMC Infect Dis (2010) 0.88
S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version. J Dtsch Dermatol Ges (2013) 0.88